DTx WEST 2023

Anand is a respected global digital health leader—most known for his insights on and experience with technology, strategy and regulatory policy. Anand has been instrumental in WellDoc’s success and the development of BlueStar®. Since joining WellDoc in 2008, he has held core leadership positions that included Chief Data Science Officer, President and Chief Operations Officer. He holds an MS and a PhD in electrical and computer engineering, and an MBA from Carnegie Mellon University.

Dr. Robinson leads Moffitt’s Center for Digital Health which
leverages the tools of IT, Health Data Services, and Digital

Innovation to expand Moffitt’s ecosystem to deliver on consumer-
oriented, real-world solutions for clinical practice, research,

education, and administrative processes. The Center for Digital
Health creates and tests new services, programs, partnerships, and
technologies that leverage digital innovations, while challenging the
status quo to reduce the cost of care, improve quality, increase
access to care, and enhance the patient experience. In addition, he
directly cares for Moffitt patients as part of the Internal and Hospital
Medicine Program.
Previously, Dr. Robinson was the Chief Transformation Officer and
Senior Vice President of Consumerism at ChristianaCare, one of the
largest health systems in the mid-Atlantic. He was responsible for
the transformation of health care delivery to advance population
health initiatives and the move from volume-based to value-based
care with a special focus on developing and managing
ChristianaCare’s consumerism and digital strategies.
Dr. Robinson is an associate professor at University of South
Florida’s Morsani College of Medicine. He is also a fellow of the
American College of Physicians and a senior fellow of the Society of
Hospital Medicine. He holds a medical degree from the David
Geffen School of Medicine at the University of California, Los
Angeles; an MBA with an emphasis in health care management from
the Wharton School at the University of Pennsylvania; and a
master’s degree in health policy research also from the University of
Pennsylvania.

Scott Barclay is a Managing Director at Insight Partners, where he focuses on investments in healthtech. His Computational Care thesis envisions the future of US and global healthcare built at the intersection of empathy and scalable technology.

Scott’s early career traversed capital markets with Banc of America Securities in Europe and the US, The Boston Consulting Group, and CVS Health. At CVS and then after, Scott helped create and scale the nation’s e-Prescribing ecosystem, running iScribe (acq Allscripts) and as Chief Strategy Officer of Surescripts.

Prior to Insight, Scott built his investing career as a healthcare angel investor and advisor (NaviHealth, Doximity, Elation) and, from 2015 – 2020, as a Partner at DCVC, a world-class early-stage deep tech venture capital firm, where he was a director or observer on the Boards of companies like Carbon Health, Freenome, SafelyYou, and many others.

Scott holds a BA in History from the University of Virginia and an MBA from INSEAD in Fontainebleau, France.

Daniel Daugaard is the CEO and Founder of Dawn Health. Bringing sound experience from the Life Science Industry, Daniel founded Dawn Health in 2016, where the company has expanded at a rapid pace under his inspiring leadership, expertise and deep-rooted passion to change the lives of patients. 

In the past two years, he and the Dawn Health team have raised substantial investments, to deploy their product platform on a global scale and secured a board of directors consisting of the highest calibre leaders from the tech industry. Daniel has grown his team by 350% in 2022 and fostered new strong partnerships with the world’s leading pharma companies, through which Dawn Health provides DTx and SaMD products build from cutting-edge software, helping patients with chronic diseases to live better lives.

Daniel has successfully transformed his Danish-based company from a design and software powerhouse into a fully-fledged product company with a clear aim to accelerate the development of regulated software products leveraged by the Dawn Platform.

David Matthews, PhD, has 15 years of experience in pharmaceuticals, medical technology, and medical research.

Before joining BrightInsight, David was a Partner in the Healthcare, Commercial, and Corporate Finance & Strategy Practices at Boston Consulting Group (BCG), where he helped lead the West Coast Medical Technology business. He served a range of healthcare clients on strategy, commercial, R&D, medical & regulatory affairs, and transformation topics, including standing up medical SaaS businesses. He was selected as an Ambassador to BCG’s internal thinktank, the Henderson Institute, where he designed and published on new economic models for biopharma products, including building the Netflix model for curative therapies. While at the firm, he received several internal awards and recognition for thought leadership, apprenticeship, and client success.

Prior to his time at BCG, David was a computational neuroscientist, with more than 20 publications and conference proceedings across machine learning, bioinformatics, brain imaging, neuroanatomy, and health economics. He has consulted independently on machine learning applications in biomedicine, built an early telemedicine app for automated melanoma detection, and taught neuroscience as an Adjunct Professor.

David holds a PhD in Computational Neurobiology from The University of California, San Diego and the Salk Institute, where he was a National Science Foundation (NSF) Research Fellow and NSF Center for Theoretical Biological Physics Fellow; and a Bachelor with honors in Molecular Biology, and minors in Bioengineering and Neuroscience, from Princeton University.

Jamie’s goal is to help others lead healthier, happier lives through improving access to quality healthcare. She is currently working towards the latter as the Vice President, Network Strategy & Operations at Maven Clinic, scaling the largest virtual clinic for women’s and family health.

Prior to Maven, Jamie served in business development, operations, and service design roles at Mount Sinai Health Partners, focused on commercializing specialty care bundles and value-based care models. Jamie started her career as a management consultant within Deloitte’s Strategy & Operations practice, focused on product commercialization and growth strategy across the healthcare, materials science, and development sectors.

Jamie graduated magna cum laude as a Merrill Presidential Scholar from Cornell University and holds a Master of Business Administration from Columbia Business School.

Dr. Maricich is a licensed, board-certified physician, investor, clinical developer, and strategist. He works
to improve patient health and our healthcare system by investing in, advising, and providing leadership
at innovative firms. At Pear Therapeutics, he leads the Clinical, Regulatory, and Quality groups as the
Chief Medical Officer and Head of Development. He leads and manages the development programs
from Discovery/TPP stage, through Translational, Clinical Development, Regulatory submission, and
review as well as Medical Affairs. In addition to overseeing subsequent pipeline programs across a
broad-spectrum of disease areas, he has led the reSET, reSET-O, and Somryst programs.
Prior to joining Pear, Dr. Maricich worked with and lead successful teams and programs at Healthcare &
Life Science/biotech (HLS) firms, including Corixa (acquired by GlaxoSmithKline), Xdynia (acquired by
Cavion), Cavion (acquired by Jazz Pharmaceuticals) and AWS. He founded a digital health firm while a
med student that used AI and NLP to structure clinical data.
Dr. Maricich completed his education and training at Harvard University, the University of Washington,
the University of Notre Dame, and the University of Virginia.

Dr. Jenna Carl is a clinical psychologist who specializes in the research and treatment of anxiety, depression, insomnia, and related mental health disorders. She has authored more than 30 peer-reviewed publications, and has presented her research and clinical trainings at leading international conferences, such as the Association for Behavioral and Cognitive Therapies, World Congress for Behavioral and Cognitive Therapies, and the American Psychological Association (APA). She serves as Chair of the APA’s Division 12 Presidential Task Force on the integration of technology and mental health treatment.

As the Chief Medical Officer at Big Health, Dr. Carl is responsible for developing evidence-based digital therapeutics for common mental health conditions that can be implemented within large employers, health plans, and health systems. She obtained her PhD in clinical psychology from Boston University, with training in the Center for Anxiety and Related Disorders at Boston University, Massachusetts General Hospital, Harvard Medical School, and the VA Health System’s National Center for Innovation to Implementation.